Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Bemana: Powering the Skilled Recruitment with Purpose and Precision

    October 27, 2025

    Insight Global: Shaping the Future of Talent Solutions Under Bert Bean’s Leadership

    October 27, 2025

    CalTek Staffing: Redefining Technical Recruitment Under Visionary Leadership

    October 27, 2025
    Facebook X (Twitter) Instagram LinkedIn
    • About Us
    • Press Release
    Tuesday, October 28
    Facebook X (Twitter) LinkedIn Instagram
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    • Home
    • Magazines
    • Featured Leaders
    • Technology
      • Big Data
      • Artificial Intelligence
      • Robotics
      • Cloud
      • Cyber Security
      • Storage
      • IoT
      • Blockchain
      • Data Analytics
    • Industry
      • Banking & Finance
      • Construction
      • Digital Marketing
      • Economy
      • Education
      • EV Industry
      • Food & Beverage
      • Healthcare
      • Legal
      • Manufacturing
      • Mining & Metals
      • Pharmaceutical
    • Testimonials
    • Events
    • Blogs
    • Awards
    • Our Clients
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    Home » Amgen Offers Massive 60% Discount on Cholesterol Drug for U.S. Patients Paying Cash
    Healthcare

    Amgen Offers Massive 60% Discount on Cholesterol Drug for U.S. Patients Paying Cash

    By Business Leaders ReviewOctober 7, 2025
    Amgen Offers Massive 60% Discount on Cholesterol Drug for U.S. Patients Paying Cash

    Key Highlights

    • Repatha is now available at a 60% lower price of $239 per month for uninsured, cash-paying U.S. patients.
    • The move comes after President Trump’s July warning urging pharma companies to match global drug prices.
    • Amgen launches direct-to-consumer sales portal ‘AmgenNow’, with plans to expand to other drugs.

    Amgen Corporation (NASDAQ: AMGN) has launched a new direct-to-consumer (DTC) sales channel for its cholesterol-lowering medication Repatha, slashing its price by nearly 60% for cash-paying U.S. patients.

    The Amgen cholesterol drug will now cost $239 per month, a move that underscores the mounting pressure on pharmaceutical companies to address high drug costs in the United States healthcare industry.

    The Thousand Oaks, California-based biotech firm said the reduced price applies to uninsured individuals purchasing directly via its newly introduced AmgenNow portal. While insured patients, who make up 98% of Repatha users, can continue accessing the drug through existing coverage plans, often paying as little as $15 per month.

    Response to Government Push on Pricing Reform

    The pricing overhaul comes in the wake of a July directive by President Donald Trump, who urged 17 leading drugmakers to align U.S. prices with international benchmarks. The administration warned that failure to act could trigger 100% tariffs on branded drugs sold domestically.

    In a statement, Amgen said its revised pricing model now reflects “the lowest rate at which Repatha is sold in any developed nation.” The company also emphasized that the AmgenNow platform simplifies access by removing traditional insurance barriers such as prior authorization or step therapy requirements.

    Industry Shifts Toward Direct Drug Sales

    Amgen joins other pharmaceutical giants such as Pfizer, which has also pledged to reduce prices and explore direct-to-consumer sales to improve affordability. The trend is gaining momentum as the Trump administration prepares to launch TrumpRx, a federal portal aimed at connecting patients directly with manufacturers offering discounted drugs.

    Amgen confirmed that its AmgenNow portal will be listed on TrumpRx once the site goes live. Additionally, GoodRx announced a collaboration with Amgen to make Repatha available at the same $239 rate across more than 70,000 U.S. pharmacies, further expanding patient access.

    About Repatha

    Approved by the FDA in 2015, Repatha works by inhibiting the PCSK9 protein, which regulates “bad” LDL cholesterol levels. The drug is widely prescribed for patients who cannot tolerate or fail to respond to statins.

    With $2.2 billion in global sales last year, Repatha remains one of Amgen’s top-performing drugs. Clinical data also show the medication significantly lowers the risk of heart attacks and strokes, even in patients with no prior cardiovascular history.

    Following the announcement on 6th October 2025, Amgen’s shares fell 1.5%, reflecting investor caution over how the company’s new pricing approach might influence long-term revenue growth.

    Related Posts

    Google and Anthropic Expand Partnership Deal To Access One Million TPUs

    October 25, 2025

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    October 17, 2025

    China Blamed for Major Breach at U.S. Cybersecurity Giant F5, Reports Bloomberg

    October 17, 2025

    Pfizer CEO Urges US Pharma Industry to Partner with China

    October 16, 2025
    Top Posts

    Google and Anthropic Expand Partnership Deal To Access One Million TPUs

    October 25, 2025

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025
    Don't Miss

    Bemana: Powering the Skilled Recruitment with Purpose and Precision

    October 27, 2025

    In a world where skilled labor shortages continue to challenge industries across the United States,…

    Insight Global: Shaping the Future of Talent Solutions Under Bert Bean’s Leadership

    October 27, 2025

    CalTek Staffing: Redefining Technical Recruitment Under Visionary Leadership

    October 27, 2025

    Google and Anthropic Expand Partnership Deal To Access One Million TPUs

    October 25, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About Us
    About Us

    Business Leaders Review is a global print and digital monthly and yearly magazine, which provides a platform to showcase business/tech leaders and their company’s profile from various sectors. Our aim is to publish the c-suite leaders stories.

    We are helping the leaders & readers to showcase their ideas and innovations to the business and tech world in this current market situation along with their awards and achievements. Doing so we hope to leverage thousands of businesses and personnel around the globe.

    Most Popular

    Google and Anthropic Expand Partnership Deal To Access One Million TPUs

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    Latest Magazines
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Our Clients
    • TECHNLOGY NEWS
    • Industry News
    • Contact Us
    • Privacy Policy
    • Reprints and Permissions
    © 2021-2025 Business Leaders Review LLC | All Rights Reserved | Empowering Communication Globally

    Type above and press Enter to search. Press Esc to cancel.